• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一项针对局限性前列腺癌患者的 PSA-TRICOM（PROSTVAC）的随机、双盲、II 期临床试验：主动监测研究中的免疫治疗预防进展。

A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study.

机构信息

Department of Urology, UC San Diego Moores Cancer Center, La Jolla, CA, USA.

National Cancer Institute, Bethesda, MD, USA.

出版信息

Eur Urol Focus. 2018 Sep;4(5):636-638. doi: 10.1016/j.euf.2018.08.016. Epub 2018 Sep 7.

DOI:10.1016/j.euf.2018.08.016
PMID:30197041
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7524340/
Abstract

The Immunotherapy to Prevent Progression on Active Surveillance Study is the first trial of immunotherapy for localized prostate cancer. We randomized active surveillance patients to PSA-TRICOM (PROSTVAC) or placebo for 5mo. Final results will be available in 2019.

摘要

主动监测研究中的免疫疗法是第一项针对局限性前列腺癌的免疫疗法试验。我们将主动监测患者随机分为 PSA-TRICOM（普罗文塔）组或安慰剂组，治疗 5 个月。最终结果将于 2019 年公布。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c922/7524340/8fa975427a66/nihms-1617421-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c922/7524340/8fa975427a66/nihms-1617421-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c922/7524340/8fa975427a66/nihms-1617421-f0001.jpg

相似文献

1
A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study.一项针对局限性前列腺癌患者的 PSA-TRICOM（PROSTVAC）的随机、双盲、II 期临床试验：主动监测研究中的免疫治疗预防进展。
Eur Urol Focus. 2018 Sep;4(5):636-638. doi: 10.1016/j.euf.2018.08.016. Epub 2018 Sep 7.
2
Development of PROSTVAC immunotherapy in prostate cancer.前列腺癌中PROSTVAC免疫疗法的发展
Future Oncol. 2015;11(15):2137-48. doi: 10.2217/fon.15.120.
3
A Phase 2, Double-blind, Randomized Controlled Trial of PROSTVAC in Prostate Cancer Patients on Active Surveillance.一项前列腺癌主动监测患者中 PROSTVAC 的 2 期、双盲、随机对照试验。
Eur Urol Focus. 2023 May;9(3):447-454. doi: 10.1016/j.euf.2022.12.002. Epub 2022 Dec 12.
4
PROSTVAC® targeted immunotherapy candidate for prostate cancer.用于前列腺癌的PROSTVAC®靶向免疫疗法候选药物。
Immunotherapy. 2014;6(3):235-47. doi: 10.2217/imt.13.176.
5
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.基于痘病毒的 PSA 靶向免疫治疗转移性去势抵抗性前列腺癌的 II 期随机对照试验的总生存分析。
J Clin Oncol. 2010 Mar 1;28(7):1099-105. doi: 10.1200/JCO.2009.25.0597. Epub 2010 Jan 25.
6
Immunotherapy for Localized Prostate Cancer: The Next Frontier?免疫疗法治疗局限性前列腺癌：下一个前沿领域？
Urol Clin North Am. 2020 Nov;47(4):443-456. doi: 10.1016/j.ucl.2020.07.008. Epub 2020 Sep 9.
7
Dramatic and prolonged PSA response after retreatment with a PSA vaccine.使用前列腺特异性抗原（PSA）疫苗再次治疗后出现显著且持久的PSA反应。
Clin Genitourin Cancer. 2013 Sep;11(3):362-4. doi: 10.1016/j.clgc.2013.01.003. Epub 2013 Jun 20.
8
Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer.由 PROSTVAC（PSA-TRICOM）引起的免疫影响，一种用于前列腺癌的治疗性疫苗。
Cancer Immunol Res. 2014 Feb;2(2):133-41. doi: 10.1158/2326-6066.CIR-13-0108. Epub 2013 Nov 4.
9
A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802.一项针对前列腺特异性抗原（PSA）痘病毒疫苗联合序贯雄激素剥夺疗法用于PSA进展患者的全国多中心2期研究：ECOG 9802。
Eur Urol. 2015 Sep;68(3):365-71. doi: 10.1016/j.eururo.2014.12.010. Epub 2014 Dec 18.
10
Current vaccination strategies for prostate cancer.当前前列腺癌的疫苗接种策略。
Eur Urol. 2012 Feb;61(2):290-306. doi: 10.1016/j.eururo.2011.09.020. Epub 2011 Oct 3.

引用本文的文献

1
Reduced recurrence of prostate cancer with novel autologous cancer vaccine (FK- PC101) post-prostatectomy: long-term results from a single-center phase 1/2 study.前列腺癌切除术后使用新型自体癌症疫苗（FK-PC101）降低复发率：一项单中心1/2期研究的长期结果
Future Sci OA. 2025 Dec;11(1):2550917. doi: 10.1080/20565623.2025.2550917. Epub 2025 Aug 29.
2
CRISPR editing to mimic porphyria combined with light: A new preclinical approach for prostate cancer.CRISPR编辑模拟卟啉病并结合光照：一种新的前列腺癌临床前研究方法。
Mol Ther Oncol. 2024 Feb 8;32(1):200772. doi: 10.1016/j.omton.2024.200772. eCollection 2024 Mar 21.
3
Prostate cancer immunotherapy: Improving clinical outcomes with a multi-pronged approach.前列腺癌免疫治疗：多管齐下改善临床结局。
Cell Rep Med. 2023 Oct 17;4(10):101199. doi: 10.1016/j.xcrm.2023.101199. Epub 2023 Sep 21.
4
Vaccines as treatments for prostate cancer.疫苗作为前列腺癌的治疗方法。
Nat Rev Urol. 2023 Sep;20(9):544-559. doi: 10.1038/s41585-023-00739-w. Epub 2023 Mar 6.
5
Immunotherapy for Prostate Cancer: A Current Systematic Review and Patient Centric Perspectives.前列腺癌的免疫疗法：当前的系统评价与以患者为中心的观点
J Clin Med. 2023 Feb 11;12(4):1446. doi: 10.3390/jcm12041446.
6
Oncolyic Virotherapy for Prostate Cancer: Lighting a Fire in Winter.肿瘤溶瘤病毒疗法治疗前列腺癌：冬日里的一把火。
Int J Mol Sci. 2022 Oct 21;23(20):12647. doi: 10.3390/ijms232012647.
7
Active surveillance versus nonradical treatment for low-risk men with prostate cancer: a review.低风险前列腺癌男性的主动监测与非根治性治疗：一项综述
Prostate Int. 2022 Sep;10(3):117-122. doi: 10.1016/j.prnil.2022.08.002. Epub 2022 Aug 24.
8
Boosting the Immune Response-Combining Local and Immune Therapy for Prostate Cancer Treatment.增强免疫反应——联合局部免疫疗法治疗前列腺癌。
Cells. 2022 Sep 7;11(18):2793. doi: 10.3390/cells11182793.
9
Vaccines for Non-Viral Cancer Prevention.非病毒癌症预防疫苗。
Int J Mol Sci. 2021 Oct 9;22(20):10900. doi: 10.3390/ijms222010900.
10
Considering the potential for gene-based therapy in prostate cancer.考虑在前列腺癌中应用基于基因的治疗方法。
Nat Rev Urol. 2021 Mar;18(3):170-184. doi: 10.1038/s41585-021-00431-x. Epub 2021 Feb 26.

本文引用的文献

1
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.局限性前列腺癌监测、手术或放疗 10 年后的结果。
N Engl J Med. 2016 Oct 13;375(15):1415-1424. doi: 10.1056/NEJMoa1606220. Epub 2016 Sep 14.
2
Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort.前瞻性多机构金丝雀前列腺癌主动监测研究（Canary PASS队列）中临床局限性前列腺癌主动监测的结果。
J Urol. 2016 Feb;195(2):313-20. doi: 10.1016/j.juro.2015.08.087. Epub 2015 Aug 29.
3
Long-term follow-up of a large active surveillance cohort of patients with prostate cancer.前列腺癌大型主动监测队列患者的长期随访。
J Clin Oncol. 2015 Jan 20;33(3):272-7. doi: 10.1200/JCO.2014.55.1192. Epub 2014 Dec 15.
4
Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer.在一个针对局限性前列腺癌的大型主动监测队列中进行疾病重新分类的延长随访及风险因素研究。
J Urol. 2015 Mar;193(3):807-11. doi: 10.1016/j.juro.2014.09.094. Epub 2014 Sep 28.
5
Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer.术前使用西妥昔单抗治疗局限性前列腺癌后，活化淋巴细胞募集至肿瘤微环境。
J Natl Cancer Inst. 2014 Sep 24;106(11). doi: 10.1093/jnci/dju268. Print 2014 Nov.
6
Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer.局部复发或进展性前列腺癌患者经直肠内前列腺疫苗接种的Ⅰ期研究。
Cancer Immunol Immunother. 2013 Sep;62(9):1521-31. doi: 10.1007/s00262-013-1448-0. Epub 2013 Jul 9.
7
Active surveillance for low-risk prostate cancer worldwide: the PRIAS study.全球低危前列腺癌的主动监测：PRIAS 研究。
Eur Urol. 2013 Apr;63(4):597-603. doi: 10.1016/j.eururo.2012.11.005. Epub 2012 Nov 12.
8
Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines.癌症疫苗临床试验的终点、患者选择和生物标志物。
Cancer Immunol Immunother. 2012 Jan;61(1):109-17. doi: 10.1007/s00262-011-1141-0. Epub 2011 Nov 26.
9
Impact of tumour volume on the potential efficacy of therapeutic vaccines.肿瘤体积对治疗性疫苗潜在疗效的影响。
Curr Oncol. 2011 Jun;18(3):e150-7. doi: 10.3747/co.v18i3.783.
10
Active surveillance program for prostate cancer: an update of the Johns Hopkins experience.主动监测前列腺癌计划：约翰霍普金斯经验的更新。
J Clin Oncol. 2011 Jun 1;29(16):2185-90. doi: 10.1200/JCO.2010.32.8112. Epub 2011 Apr 4.